BCIQ Profiles

Company Profile Report
0603 ECP Interius
BioCentury & Getty Images

Emerging Company Profile

Interius design: Penn spinout gets specific with in vivo CAR Ts

Emerging Company Profile: Philadelphia cell and gene therapy play has $76M from Cormorant, Fairmount to get to clinic

With $76 million in a series A funding, Penn spinout Interius is developing in vivo CAR Ts for hematologic cancers.

Jun 4, 2021 | 1:13 AM GMT

Cell and gene therapy company Interius has $76 million from a series A funding led by Bihua Chen’s Cormorant and Fairmount and the guidance of Executive Chairman Lonnie Moulder to develop an in vivo CAR T technology spun out of the University of Pennsylvania that the company says gives it the specificity it needs to deliver genetic payload

Read the full 1176 word article

How to gain access

Continue reading with a
two-week free trial.